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Thanatophoric dysplasia (TD) is the most common neonatal lethal 
skeletal dysplasia, and it is regularly encountered in the context of 
antenatal diagnosis and autopsy. This review of the disorder is based 
upon personal experience and data concerning 19 cases archived 
in the Division of Pathological Anatomy, University of Cape Town 
(UCT).
Professor Peter Beighton had a special interest in genetic bone 
disorders and following his appointment at UCT in 1972 he 
established a special clinic for affected persons at the Princess Alice 
Orthopaedic Hospital. He also undertook diagnostic screening 
at facilities for physically handicapped persons throughout 
South Africa. These activities led to the publication of his early 
monographs[1-3] and to his involvement in the International Classifi-
cation of Osteochondrodysplasias.[4] After mandatory retirement 
in 1999, he extended his interest in skeletal dysplasias to neonates, 
stillbirths and fetuses and assisted me with my research in this 
field. Together we have co-authored 11 articles concerning the most 
severe and lethal skeletal dysplasias. In early intrauterine life, the 
radiological features may be poorly developed and the pathological 
changes in the bones more difficult to determine than in a full-term 
pregnancy. Information from prenatal ultrasonic imaging from 12 
weeks’ gestation onwards is now available and it is invaluable in the 
early detection and diagnosis of a specific skeletal dysplasia in order 
to facilitate appropriate obstetrical and genetic management.
The incidence of type 1 TD (TD1) is variously quoted as 1 in 
20 000 - 40 000 stillborn and liveborn infants (MIM 187600)[5] or 1 
in 33 000 - 47 000 live births[6]]. The condition was initially termed 
thanatophoric dwarfism in 1967,[7] and a decade later the name was 
changed to thanatophoric dysplasia. The name was derived from the 
Greek word thanatos meaning ‘death’ and phoros meaning ‘provoking’.
Manifestations
TD is traditionally divided into two forms on a basis of the 
radiographic appearances – TD1 with curved femora and usually a 
normal skull and type 2 (TD2) with straight femora and frequently a 
trilobal clover-leaf skull.
Phenotypically, there is marked symmetrical shortening of the 
limbs with redundant skin folds, shortening of hands and feet, 
macrocephaly with frontal bossing, a depressed nasal bridge, small 
chest, large protuberant abdomen, and a trunk of relatively normal 
length (Fig. 1). The radiological features of TD1 are characteristic 
when the infant is delivered at term – macrocephaly, symmetrical 
micromelic shortening of long bones, metaphyseal cupping of the 
proximal femora, telephone-receiver shaped femora, hypoplastic 
or small scapulae, platyspondyly with H-shaped vertebrae in the 
anterior-posterior view, a narrow thorax with short ribs, and 
characteristic triradiate acetabulum with short sacrosciatic notches. 
Interpediculate narrowing of the spinal canal evident on lateral views 
results in damage to the spinal cord in rare survivors. In TD2, the 
skull has a marked anterior depression forming the trilobal clover-
leaf skull.[8]
Bone radiographic morphometry shows that longitudinal bone 
growth is not equally inhibited across the growth plate, resulting in 
the lateral spurs at the metaphyseal growth plates. The platyspondyly 
is due to a reduced height of the anterior ossification centres 
of the vertebral bodies, while laterally there is no restriction in 
growth. Interplay between mechanical factors and the effects of the 
underlying mutation are additional factors in this process.[9]
Autopsy findings
At postmortem, the head is macrocephalic due to macroencephaly 
and symmetrical deep grooves are present on the basal surfaces 
of the temporal lobes of the brain. Histologically, the ends of the 
long bones show markedly disordered growth plates. The normal 
growth plate has three zones – the resting zone with disordered 
chondrocytes and abundant matrix, the proliferative zone, and 
the hypertrophic zone where the chondrocytes die. Below the 
hypertrophic zone is the zone of provisional calcification, then 
the primary and secondary spongiosum. In TD1, the resting zone 
is uninvolved. The proliferative and hypertrophic zones show 
variable disorganisation with complete absence in some areas and 
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Fig. 1. Immature fetus with TD1 with macrocephaly, frontal bossing, 
depressed nasal bridge, small chest, protuberant abdomen and short 
symmetrical bowed limbs.
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focal columns in others. A typical horizontal band extends from 
the perichondrial fibrous tissue at the periphery into the growth 
plate and there is transformation of this mesenchymal tissue into 
irregular, poorly orientated bony trabeculae. The cartilaginous bars 
are reduced in number and are thin and distorted. Perichondrial 
ossification extends above the level of endochondral ossification. 
The value of histological assessment of the growth plate in the 
diagnosis of TD1 has been known since 1979 (Fig. 2).[10]
The ultrasonographic, radiological and histological features in 
fetuses and newborns are well documented.[11] Young fetuses pose 
a special challenge to diagnosis as diagnostically characteristic 
radiological features may be absent. Ultrasound shows severely 
shortened and bowed long bones, a narrow thorax filled by the heart, 
a protuberant abdomen and bossing of the skull. In young fetuses, 
the ultrasonographic diagnosis may not be specific. Nevertheless, 
detection of severe shortening of limbs with bowing and severe 
thoracic hypoplasia suggest a lethal skeletal dysplasia with pulmonary 
hypoplasia, which is usually a sufficient indication for termination of 
pregnancy.
The central nervous system abnormality is not secondary to the 
bone changes in the skull, such as synostosis which occur late in 
gestation, but due to the underlying FGFR3 mutation. Fibroblast 
growth factors (FGFs) 1 - 4 are expressed in the developing brain. 
Using a mouse model, it has been shown that FGFR3 is involved in 
area patterning, progenitor proliferation and a reduction in apoptosis 
within the brain. The most typical neuropathological changes are 
megaloencephaly, dysplasia of the hippocampus, rudimentary 
dentate nucleus, polymicrogyria, temporal lobe hyperplasia, 1 - 
5 abnormal deep transverse sulci on the basal surface, subependymal 
neuronal heterotopia and subarachnoid neuroglial heterotopia 
(Fig. 3).[12] Temporal lobe ventriculomegaly is common, but severe 
hydrocephalus occurs only in 18% of cases due to a small foramen 
magnum. The cerebellum may be hypoplastic or normal. The 
diagnostic basal transverse sulci are seen at 20 weeks’ gestation when 
the brain normally has a smooth surface. The abnormal sulcation 
on the medial aspects of both temporal and occipital lobes has been 
identified on antenatal sonography at 21 weeks and confirmed on 
antenatal MRI, postnatal MRI and at postmortem.[13]
Molecular pathogenesis
The inception of the molecular age brought major changes to the 
former categorisation of skeletal dysplasias which has now been 
supplemented or replaced by a molecular classification.[14] TD1 
now falls under the broad group of the Fibroblast Growth Factor 
Receptor 3 (FGFR3) family [FGFR3, OMIM 134934]. The first 
activating or gain-in-function mutation in FGFR3 receptor tyrosine 
kinase that binds fibroblast growth factors was discovered in 1994 
in achondroplasia.[15,16] Other conditions associated with mutations 
in this gene include TD2. Numerous somatic mutations that cause 
diverse conditions such as specific skeletal dysplasias, skin disorders 
and malignancies have also been identified.
The FGFR3 gene encodes a protein, predominantly in bone-
producing cells, which straddles the cell membrane with the inner 
end within the cell. The outer end projects from the surface and 
growth factors attach to it, resulting in its activation and action 
on bone. The gene regulates skeletal development by degradation 
of the bone morphogenetic protein (BMP) type 1 receptor. It has 
a negative effect on chondrogenesis/endochondral bone growth 
via inhibition of BMPR1a, which is required for chondrocyte 
differentiation.[17]
TD1 may result from a single amino acid substitution in either 
the extracellular or intracellular domains of the protein. Examples 
involving the extracellular domain include p.R248C (c.742C>T); 
p.Y373C (c.1118A>G).[18,19] Stop codon mutations have been reported: 
p.X807G (c.2419T>G); p.x807R (c.2419T>A); p.X807C (c.2421A>T) 
and these mutations result in elongation of the protein.[20]
Both K650M and K650E mutations in the FGFR3 gene show 
abnormal cellular location to the endoplasmic reticulum[21] and they 
activate downstream signalling intermediates such as ERKMAP 
kinase.[22] These two mutations can be recognised by light microscopy 
as large cytoplasmic inclusion bodies that stain positively with 
antibodies to FGFR3 protein.[23] Other mutants such as R248C and 
Y373C signal from the cell membrane and cause severe skeletal 
dysplasia.[24]
Numerous studies have involved investigations of mutations 
in TD1. The largest series consisted of 91 cases of TD1 and TD2 
with FGFR3 mutations identified in the International Skeletal 
Dysplasia Registry (ISDR).[25] The most common mutation was 
R248C, occurring in 50% of cases of TD1, followed by Y373C in 
Fig. 2. Masson’s trichrome stain shows histology of the markedly disordered 
growth plate with a horizontal band extending into the growth plate 
indicated by a star; the short arrow shows the proliferative zone, the long 
arrow shows the short chondrocyte columns – the arrowhead shows the 
disordered metaphysis.
Fig. 3. Inferior surface of the brain with the basal surfaces of the temporal 
lobes showing deep symmetric grooves diagnostic of TD1.
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20%. These cases had more severe radiological manifestations than 
TD1 with R248C, but there was phenotypic overlap. Nineteen cases 
with TD2 from the ISDR had the K650E mutation and showed 
better preservation of the growth plate compared with TD1. 
Two mutations in the FGFR3 gene result in virtually all cases of 
achondroplasia, which is allelic with TD2. The N540K mutation 
alone results in the less severe phenotype of hypochondrodyplasia.
In 2014, Xue, et al.[26] reported an update from the ISDR in which 
mutation analysis involved sequencing of the entire coding region 
in 324 cases, including achondroplasia and hypochondroplasia. 
This extensive series showed that 90% of TD1 mutations were either 
pArg248Cys (66%) or pTyr373Cys. The third most common was a 
stop codon mutation pX807 and the fourth was pSer249Cys. The 
mutation pGlu370Cys accounted for 2.3% and pLys650Met for 1.2%. 
This information is extremely useful when designing and costing 
commercial tests for TD1.
Mutations cause activation of FGFR3 by different mechanisms. 
Extracellular FGF ligands form dimers. The TD1 mutation 
Y373C forms covalent bound dimers between cysteine residues 
near the juxtamembrane domain. Amino acid substitutions in the 
intracellular domain, such as K650M in TD 1/SADDAM or K650E 
in TD2, mimic conformational changes resulting in dimerisation and 
autophosphorylation.[27]
Low levels of activity require FGF ligand for activation: high levels 
of activity, as occurs with R248C and Y373C mutations, result in 
spontaneous dimerisation and are independent of ligand. Different 
amino acid substitutions cause differing degrees of activation 
of FGFR3, which translates into varying levels of chondrocyte 
inhibition. The most severe inhibition will result in the most severe 
degree of skeletal dysplasia.
In the absence of a mutation, the inhibition of chondrocytes via 
FGFR3 can be regarded as senescence, which can be experimentally 
reversed. Elsewhere in the body this senescence represents a natural 
barrier against tumour development. In embryogenesis, newly 
formed chondrocytes trigger strong initiation of FGFR3 expression 
as required for differentiation.
FGFR3 is a physiological negative regulator of bone growth. In 
humans, loss of function of FGFR3 causes an autosomal recessive 
syndrome CATSHL, which is characterised by camptodactyly, 
hearing loss and skeletal overgrowth.[28] Somatic mutations identical 
to those associated with TD1 can cause skin overgrowth or cancer, 
demonstrating that the TD mutation can act as an oncogene.[29] The 
growth inhibitory role of FGFR3 in cartilage is unique in comparison 
to its aberrant signalling in other tissues.[30]
Aberrant signalling in the RAS/ERK pathway due to FRGF3 
results in skeletal dysplasias. The signaling interferes with cyclin D3 
complexes in the G1 phase of the cell cycle. There is an increase in cell 
cycle inhibitors that inhibit kinase activities. FGFR3 activation causes 
increased cell cycle inhibitors that prolong ERK activation only in 
chondrocytes so that the pathology is limited to the growth plate, as 
seen in skeletal dysplasias.
Animal studies in mice have produced an equivalent model to 
TD1 by introducing the S365C mutation into exon 10 of mouse 
FGFR3. However, the mutant mouse has severe dwarfism but no 
pulmonary hypoplasia, and the condition is therefore non-lethal. 
Other mouse models include short stature and a dome-shaped skull 
when the K6434E mutation is introduced into FGFR3. This mouse 
has a small thoracic cage and lethality. Mutation G369C provides an 
animal model for achondrogenesis. Regular subcutaneous injections 
of parathyroid hormone (PTH) permit a larger thorax to develop, 
thereby preventing pulmonary hypoplasia and causing an increase 
in length of long bones and a round head in the mouse models.[31] 
For these reasons, mouse models can be used for testing potential 
therapies.
Antenatal diagnosis in TD
Early first-trimester prenatal diagnosis of skeletal dysplasia requires 
expertise. At 12 weeks, there may be subtle features such as frontal 
bossing, rarely an increase in nuchal translucency and short limbs. 
Early in the second trimester, a small thorax and short, bowed long 
bones may be demonstrated particularly by 2D and 3D ultrasound 
imaging. Ultrasound alone provides a specific antenatal diagnosis 
in 1/3 - 2/3 of cases.[32] The size of the thorax alone does not always 
indicate lethality, but parameters such as thoracic circumference and 
the thoracic-to-abdominal ratios may be more helpful.[33]
If the necessary facilities are available, mutational analysis during 
pregnancy is useful when TD is suspected.[34] The FGFR3 gene 
consists of 19 exons and 18 introns spanning 16.5kb[35] and screening 
for the most frequently occurring mutations is cost effective.
Genotyping of mutations can be performed by high-resolution 
melting analysis. R248C is the most common mutation. Exon 7 was 
analysed in 10 samples with TD1 and 30 controls using melting curve 
analysis with a high-resolution melting instrument. This mutation was 
present in all 10 samples, giving a sensitivity and specificity of 100%.[36]
Other strategies for molecular testing use hot-spot exons 7, 10, 
15 and 19 analysis with 80 - 90% sensibility. If hot spot exons are 
negative, then a search for rare mutations using sequential analysis 
of FGFR3 gene is performed.[37] The nucleotide sequence of FGFR3 is 
highly conserved between man and mouse.
Future prospects
In the context of the FGFR3 group of disorders, postnatal treatment 
of achondroplasia is becoming a possibility in 2015 in First-World 
countries, raising hope for therapeutic intervention in certain skeletal 
dysplasias. Nevertheless, therapy for TD remains highly unlikely at 
the present time.
References
1. Beighton P. Inherited Disorders of the Skeleton. Edinburgh: Churchill Livingstone; 1978.
2. Beighton P, Cremin B. Sclerosing Bone Dysplasias. Heidelberg: Springer-Verlag; 1980.
3. Horan F, Beighton P. Orthopaedic Problems in Inherited Skeletal Disorders. Heidelberg: Springer-
Verlag; 1982.
4. Beighton P, Giedion A, Gorlin R, et al. International classification of osteochondrodysplasia. 
International Working Group on Constitutional Diseases of Bone. Am J Med Gen 1992;44(2):223-229.
5. Oriola IM, Castilla EE, Barbosa-Neto JG. The birth prevalence rates for sketal dysplasia. J Med Genet 
1982;23(4):328-332.
6. Waller DK, Correa A, Vo TM, et al. The population-based prevalence of achondroplasia and 
thanatophoric dysplasia in selected regions of the US. Am J Med Genet A 2008;146A:2385-2389. 
DOI:10.1002/ajmg.a.32485
7. Maroteaux,P, Lamy M, Robert JM. Le nanisme thanatophore. Presse Med 1967;75:2519-2514.
8. Kozlowski K, Beighton P. Gamut Index of Skeletal Dysplasias. An Aid to Radiodiagnosis. 3rd ed. 
Heidelberg: Springer-Verlag; 2001. p. 223-224.
9. Pazzaglia UE, Donzelli CM, Izzi C, et al. Thanatophoric dysplasia. Correlation among bone Xray 
morphometry, histopathology, and gene analysis. Skeletal Radiol 2014;43(9):1205-1215. DOI:10.1007/
s00256-014-1899-1
10. Sillence DO, Horton WA, Rimoin DL. Morphologic studies in the skeletal dysplasias. Am J Pathol 
1979;96(3):813-870.
11. Brons JTJ, Van der Harten HJ. Skeletal Dysplasias. Pre- and Postnatal Identification. An 
Ultrasonographic, Radiologic and Pathologic Study. Amsterdam: Free University Hospital; p. 111-142.
12. Hevner RF. The cerebral cortex malformation in Thanatophoric Dysplasia – neuropathology and 
pathogenesis. Acta Neuropathol 2005;110:208-221.
13. Fink AM, Hingston T, Sampson A, et al. Malformation of fetal brain at 21 weeks fetal ultrasonography 
confirmed by antenatal MRI, postmortem imaging and autopsy. Pediatr Radiol 2010;40(Suppl 1):S134-
137. DOI: 10.1007/200247-010-1697-4
14. Nikkels PGI. Diagnostic approach to congenital osteodysplasia at autopsy. Diagnostic Histopathology 
2009;15-9 Mini-Symposium: Osteoarticular Pathology Elsevier Ltd
15. Shiang R, Thampson LM, Zhi YZ, et al. Mutation in the transmembrane domain of FRGF3 causes the 
most common form of dwarfism, achondroplasia. Cell 1994;78(2):335-342.
16. Rousseau F, Bonaventure J, Legai-Mallet L, et al. Mutation in the gene encoding fibroblast growth 
factor receptor 3 in achondroplasia. Nature 1994;371(6494):252-254.
17. Qi H, Jin M, Duan Y, et al. FGFR3 induces degradation of BMP type 1 receptor to regulate skeletal 
development. Biochim Biophys Acta 2014;1843(7):1237-1247.
18. Tavormina PL, Shiang R, Thompson LM, et al. Thanatophoric dysplasia (type 1 and 2) caused by 
distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995;9(3):321-328.
19. Kitoh H, Brodie SG, Kupke KG, et al. Lys650Met substitution in the tyrosine kinas domain of the 
fibroblast growth factor receptor 3 gene causes thanatophoric dysplasia Type 1. Mutations in brief 
no.199. Online. Hum Mutat 1998;12(5):362-363.
20. Rousseau F, el Ghouzzi V, Delezoide AL, et al. Missense FGFR3 Mutations create cysteine residues in 
thanatophoric dysplasia type. Hum Mol Genet 1996;5(4):509-512.
S53       June 2016, Vol. 106, No. 6 (Suppl 1)
HOW HUMAN GENETICS CAME TO SA
21. Raffioni S, Zhu YZ, Bradshaw RA, et al. Effect of transmembrane kinase domain mutation on fibroblast 
growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine 
kinase activity. J Biol Chem 1998;273(52):35250-35259.
22. Lievens PM, Liboi E. The thanatophoric dysplasia type II mutation hampers complete maturation 
of fibroblast growth factor receptor 3 (FGFR3) which activates transcription 1(STAT1) from the 
endoplasmic reticulum. J Biol Chem 2003;278(19):17344-17349.
23. Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR. Platyspondylic lethal 
skeletal dysplasia, San Diego type, is caused by FGFR3 mutation. Am J Med Genet 1999;84(5):476-480.
24. Krejci P. The paradox of FGFR3 signaling in skeletal dysplasia: Why chondrocytes growth arrest while 
other cells overproliferate. Mutant Res Rev Mutat Res 2014;759:40-48. DOI:10.1016/j.mrrev.2013.11.001
25. Wilcox WR, Tavormina PL, Krakow D, et al. Molecular, radiologic and histologic correlation in 
thanatophoric dysplasia. Am J Med Genet 1998;78(3):274-281.
26. Xue Y, Sun A, Mekikia PB, et al. FGFR3 mutation frequency in 324 cases from the International 
Skeletal Dysplasia Registry. Mol Genet Genomic Med 2014;2(6):497-503. DOI:10.1002/mgg3.96
27. Webster MK, D’Avos PY, Robertson SC, et al. Profound ligand-independent kinase activation of 
FGFR3 by the activation loop mutation responsible for a lethal skeletal dysplasia, Thanatophoric 
Dysplasia Type II. Molec Cell Biol 1996;16(8):4081-4087.
28. Toydemir RM, Brassington AE, Bayrak-Toydemir P, et al. A novel mutation in FGFR3 causes camptodactyly, 
tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet 2006;79(5):935-941. DOI:10.1086/508433
29. Foldynova-Trantirkova S, Wilcox WR, Kreici P. Sixteen years & counting: The current understanding 
of Fibroblast Growth Factor Receptor 3 signaling in skeletal dysplasia. Hum Mutat 2012;33(1):29-41. 
DOI:10.1002/humu.21636
30. Krejci P. The paradox of FGFR3 signaling in skeletal dysplasia; why chondrocytes growth 
arrest while other cells proliferate. Mutat Res Rev Mutat Res 2014;759:40-48. DOI:10.1016/j.
mrrev.2013.11.001
31. Xie Y, Su N, Jin M, et al. Intermittent PTH (1-34) injection rescues the retarded skeletal dysplasia 
postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. Hum Mol 
Genet 2012;21(18):3941-3955. DOI:10.1093/hmg/dds181
32. Parilla BV, Leeth EA, Kambich MP, Chilis P, MacGregor SN. Antenatal detection of skeletal dysplasia. 
J Ultrasound Med 2003;22(3):255-258.
33. Wong HS, Kidd A, Zuccullo J, et al. A case of thanatophoric dysplasia. Early prenatal 2D and 3D 
sonographic findings and molecular confirmation of diagnosis. Fetal Diagn Ther 2008;24(1):71-73. 
DOI:10.1159/000132411
34. Chen CP, Chern SR, Wang W, Wang TY. Second-trimester molecular diagnosis of a heterozygous 
(R248D) mutation in the FGFR3 gene in a thanatophoric dysplasia variant following suspicious 
ultrasound findings. Ultrasound Obstet Gynecol 2001;17(3):272-273.
35. Perez-Castro AV, Wilson J, Altherr MR, et al. Genomic organization of the human fibroblast growth 
factor receptor 3 (FGFR3) geneand comparative sequence analysis with the mouse FGFR3 gene. 
Genomics 1997;41(1):10-16.
36. Liu YN, Li R, Li DZ. Genotyping of the C742T mutation of the FGFR3 gene causing type 1 thanatophoric 
dysplasia by high-resolution melting analysis. J Matern Fetal Neonatal Med 2011;24(1):186-188. 
DOI:10.3109/14767058.2010.482621
37. Pazzaglia UE, Donzelli GM, Izzi C, et al. Thanatophoric dysplasia. Correlation among bone X-ray, 
morphometry, histopathology, and gene analysis. Skeletal Radiol 2014;43(9):1205-1215.
